1.Effect of Wendan Tang adjuvant therapy on serum immune antibodies and efficacy in patients with phlegm dampness infertility
Shisheng YANG ; Kuansheng CHEN
Chinese Journal of Biochemical Pharmaceutics 2015;(11):78-80
Objective To analyse effect of Wendan Tang adjuvant therapy on serum immune antibodies and efficacy in patients with phlegm dampness infertility.Methods 52 patients who were diagnosed with phlegm dampness infertility were collected.All patients were randomly divided into experimental group and control group, 26 cases in each group.Patients in control group received treatment with clomifene citrate capsules, patients in experimental group were given Wendan Tang treatment on the basis of control group treatment, after the treatment, the serum levels of Sp17Ab, AcrAb and treatment effect were detected in all patients.Results After treatment, compared with control group, the serum level of Sp17Ab was lower in experimental group(P<0.05); the serum level of AcrAb was lower in experimental group(P<0.05); the pregnancy rate was higher in experimental group(P<0.05).Conclusion The Wendan Tang adjuvant therapy can significantly reduce the serum levels of Sp17Ab and AcrAb in patients with phlegm dampness infertility,improve the pregnancy rate, improve the treatment effect.
2.Studies on apoptosis and bcl-2/bax gene expression induced by somatostatin analogue in human cholangiocarcinoma cell line
Hua CHEN ; Zhenping HE ; Kuansheng MA
Chinese Journal of General Surgery 2001;0(10):-
Objective To study the effect of somatostatin analogue (SMS201-995,SMS) on apoptosis of human cholangiocarcinoma SK-ChA-1 cells and apoptosis-regulated gene bcl-2 and bax. Methods The changes of apoptosis and bcl-2/bax gene expression were detected by DNA gel electrophoresis, flowcytometric analysis and immunohistochemistry, in situ hybridization methods in cholangiocarcinoma SK-ChA-1 cells after treated with SMS(100?ng/ml) for 6, 12 and 24 hours.Results The characteristic ladder was not detected by agarose gel electrophoresis after treated with SMS(100?ng/ml) for 6 hours. When the cells were treated for 12 and 24 hours, the ladder of DNA electrophoresis was observed. While the cells were treated with SMS for 6, 12 and 24 hours, the percentage of annexin V-positive cells were (22?5)% ,(39?7)% and(58?10)%. Besides,SMS inhibited bcl-2 protein expression and increased bax protein and mRNA expression. Conclusion SMS can induce SK-ChA-1 cell apoptosis mainly with regulation of bcl-2 and bax gene expression.
3.Multiple electrodes radio-frequency in treating complications of liver tumor and its prevention and treatment.
Kuansheng MA ; Min CHEN ; Xiaolan HUANG ; Jiahong DONG
Chinese Journal of Practical Surgery 2001;21(2):93-94
ObjectiveTo study the multiple electrodes radio-frequency in treating complications of liver tumor and its prevention and treatment. Methods 114 patients of liver tumor were treated with multiple electrodes radio-frequency for 170 times,clinical complication and its prevention and cure were observed. ResultsThe rate of complication was 9.6%. The complications included 1 case of colon perforation, 4 cases of skin burn, 5 case of hydrothorax, 1 case of subcutaneous hemorrhage, but no patient died from these. ConclusionThe rate of complications of multiple electrodes radio-frequency treatment for liver tumor is low and the complications can be prevented and cured.
4.Effect of RFA combined with TACE for treatment of early hepatocellular carcinoma with liver cirrhosis
Yu WANG ; Kuansheng MA ; Jian CHEN ; Juxian SONG
Journal of Regional Anatomy and Operative Surgery 2015;(3):273-276
Objective To assess the effect of radiofrequency ablation ( RFA) combined with transcatheter hepatic arterial chemoemboli-zation ( TACE) and radiofrequency ablation alone for the treatment of early hepatocellular carcinoma ( HCC) with liver cirrhosis. Methods The data of all the patients that were given RFA+TACE (n=51) and RFA (n=53) treatments in our hospital from January 2008 to De-cember 2013 were analyzed. The demographic data,process of operation,postoperative complications,postoperative recovery and follow-up of the patients in two groups were carefully compared. Results The average follow-up time was (37. 6 ± 20. 7)months,38 cases were dead and 76 cases were survival. The overall survival rates of 1 years,3 years,5 years after operation were respectively 96. 5%,78. 7%,65. 9% in RFA+TACE group and 94. 3%,75. 6%,62. 3% in RFA group. Tumor-free survival rates of 1 years,3 years,5 years were 75. 4%,47. 3%, 32. 6% in RFA+TACE group,and 63. 1%,37. 2%,22. 4% in RFA group. Conclusion For patients with early hepatocellular carcinoma with liver cirrhosis,RFA combined with TACE have higher tumor free survival rate than RFA alone in the treatment of early hepatocellular carcinoma,but no difference in overall survival rate. The results still need to be validated by prospectively randomized controlled trials.
5.Effects of somatostatin analogues on the cell cycle and the related gene expression in human cholangiocarcinoma cell line SK-ChA-1
Hua CHEN ; Zhenping HE ; Kuansheng MA ; Zhong YANG ;
Journal of Third Military Medical University 2003;0(07):-
Objective To investigate the effects of somatostatin analogue (SMS201 995, SMS) on the cell cycle of human cholangiocarcinoma SK ChA 1 cells and cell cycle regulated gene cyclinD1 and p16. Methods SK ChA 1 cells were synchronized by serum starvation. Cells at different phases were harvested at 48 h after SMS treatment of the synchronized SK ChA 1 cells. The distribution of cell cycles was analyzed by flow cytometry. The expression levels of cyclinD1 and p16 gene were detected by SABC immunohistochemistry and in situ hybidization. Results SMS could significantly inhibit the poorly serum synchronized SK ChA 1 cells to reenter the cell cycle from G 0/G 1 phase at 6 h and 12 h ( P
6.Efficacy evaluation of laparoscopic surgery in the treatment of 128 patients with liver cancer
Shuguo ZHENG ; Jianwei LI ; Jian CHEN ; Yudong FAN ; Zhongfang JIE ; Kuansheng MA ; Shuguang WANG ; Ping BIE
Chinese Journal of Digestive Surgery 2010;9(1):35-37
Objective To investigate the value of laparoscopy in the treatment of liver cancer.Methods The clinical data of 128 liver cancer patients who received laparoscopic surgery at Southwest Hospital from March 2007 to October 2009 were retrospectively analyzed.Of all patients,116 were with primary liver cancer,and 12 with metastatic liver cancer.There were 107 patients who received laparoscopie bepatectomy,15 received laparoscopic radiofrequency ablation(RFA)and 6 received laparoscopic ligation of the right branch of portal vein.Results Of the 107 patients who received laparoscopic bepatectomy,7 were converted to open surgery,and 5 were converted to hand-assisted laparoscopic hepatectomy.Anatomical hepatectomy was performed on 88 patients,including left lateral lobectomy on 21,left hemihepatectomy on 15,extended left hemihepatectomy on 2,medial lobectomy on 1,right hemihepatectomy on 11,right posterior lobeetomy on 9 and hepatic segmentectomy on 29.Combined hepatic resection was performed on 4 patients,and nonanatomical hepatectomy on 15.The mean oporatire time and blood loss were(228±92)minutes and(393±213)ml,with no operative mortality.The mean postoperative hospital stay was(8±4)days,and the incidence of complications was 15%(16/107).A total of 126 patients were followed up for 1-42 months,12 patients with laparoscopic hepatectomy died within 16 months,with the mean survival time of(118±7)weeks and the mean tumor free survival time of(105±7)weeks;2 patients with laparoscopic RFA died within 11 months:2 patients with laparoseopie ligation of the right branch of portal vein received two-stage radical resection.Conclusion Laparoscopic surgery is safe and feasible with the advantages of minimal operative trauma and quick recovery of patients when it is applied to the treatment of liver cancer.
7.Simultaneous super-selective hepatic arterial and portal vein embolization for staged hepatectomy in patients with hepatocellular carcinoma and cirrhosis
Geng CHEN ; Lin ZHANG ; Yi ZHOU ; Yujun JI ; Kuansheng MA ; Feng XIA
Chinese Journal of Hepatobiliary Surgery 2019;25(4):249-253
Objective To study the feasibility and safety of simultaneous super-selective hepatic arterial and portal vein embolization for staged hepatectomy (ASAPS) in the treatment of patients with hepatocellular carcinoma (HCC) and cirrhosis.Methods The clinical data of 8 patients with HCC who underwent ASAPS at the First Affiliated Hospital of the Army Medical University from December 2016 to January 2018 were retrospectively analyzed.All the patients,including 7 males and 1 female with an average age of 44.3± 9.2,were diagnosed to have cirrhosis with insufficient volume of future liver remnant (FLR).Portal vein embolization (PVE) and super-selective hepatic arterial embolization (SHAE) were performed simultaneously.The patients were then closely monitored for the volumes of FLR.Once the FLR achieved the target volume,a second staged resectional surgery would be performed.The postoperative major complications,laboratory tests and patient long-term survival were studied.Results The ratio of FLR to the average standard liver volume (SLV) increased from (28.5±5) % to (49.6±7.3) % following the first-stage procedure.All the patients underwent liver resection successfully.The average second-stage operation time was 342.6±92.8 min,and the intraoperative blood loss was 743.8±432.1 ml.Both the postoperative serum alanine amin otransferase (ALT) and aspartate aminotransferase (AST) levels were elevated remarkably and then droppedto the near normal levels.All the patients were discharged home without any severe complications.Among them,3 patients relapsed early in the postoperative period,5 survived without recurrence,and 3 survived for over 1 year.Conclusions The first-stage surgery of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) using ASAPS was minimally invasive.The volume growth rate of the FLR after ASAPS was comparable to that of the conventional first stage of ALPPS.In conclusion,ASAPS is a promising alternative to the traditional ALPPS as the first-line treatment of patients with insufficient FLR.
8.Application of radiofrequency ablation assisted ALPPS in liver cancer patients with insufficient future liver remnant
Ying CHEN ; Xiaofei WANG ; Kai FENG ; Yujun JI ; Qingsong DENG ; Kuansheng MA
Chinese Journal of Hepatobiliary Surgery 2022;28(11):812-816
Objective:To analyze the apply effect of radiofrequency ablation assisted associating liver partition and portal vein ligation for staged hepatectomy (RALPPS) in liver cancer patients with insufficient future liver remnant (FLR).Methods:The data of 29 patients who underwent RALPPS in the First Affiliated Hospital of the Army Military Medical University from June 2014 to July 2020 were analyzed, including 25 males and 4 females, aged (46.6±9.9) years. The patients were divided into the second stage group (completed the second stage operation, n=18) and the first stage group (completed only the first stage operation, n=11) according to whether they had successfully completed the second stage operation. FLR, percentage of FLR in standard liver volume (percentage of FLR), growth rate of FLR, liver function after operation, operation time and radiofrequency ablation time of first stage operation, surgical complications were compared between the two groups. Results:The percentage of FLR before the first stage operation was (30.0±7.0)% in 29 patients, and the second stage operation was completed in 18 patients (62.1%). After the first stage operation, the aspartate aminotransferase and alanine aminotransferase in the second stage group were 519.0 (362.9, 696.0) U/L and 391.8 (297.2, 591.1) U/L, which were better than those of the first stage group 931.0 (711.7, 1131.9) U/L and 851.3 (426.6, 888.0) U/L (both P<0.05). There was no significant difference between the two groups in FLR and percentage of FLR before the first stage operation, duration time, amount of bleeding and time of radiofrequency ablation of the first stage operation (all P>0.05). In the second stage group, the interval between two operations was (21.6±6.7) days, the FLR before the second stage operation was (623.2±101.8) cm 3, the FLR percentage was (49.0±7.0)%, and the FLR growth rate was (19.0±5.0)%. In the first stage group, there were 11 patients (100.0%) who developed complication after first stage operation, induding 7 patients (63.6%) with complication above Clavien-Dindo grade Ⅲb. In the second stage group, 18 patients (100.0%) developed complication after the first stage operation. There were no complication above grade Ⅲb. The causes of 11 patients who did not completed secondary surgery included poor liver function and insufficient FLR in 4 patients, tumor progression in 6 patients, and death in 1 patient. Conclusion:RALPPS is a therapeutic option for liver cancer patients with insufficient FLR, and the therapeutic effect is reasonable.